Ajai Chari, MD, University of California San Francisco, explores the challenges that accompany integrating chimeric antigen receptor (CAR) T-cell therapies into multiple myeloma treatment.
Reflections on a recent NEJM publication highlight the importance of identifying and addressing the pathologic process of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback